Rotavirus Aşıları
Yıl: 2015 Cilt: 9 Sayı: 4 Sayfa Aralığı: 166 - 174 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Rotavirus Aşıları
Öz: Rotavirus, infantlarda ve küçük çocuklarda ağır gastro- enteritin en sık nedenidir. Dünya genelinde 5 yaş altıishalli çocuklardaki hastane yatışlarının yaklaşık%40ında etken rotavirustur. Demokratik virus olarak dabilinen rotavirus, hijyen koşullarından bağımsız olarak,gelişmiş ve gelişmekte olan ülkelerde benzer sıklıktagörülür. Çocukların hemen hepsi 5 yaşına kadar, en az1 kez rotavirusla enfekte olmaktadır. Ancak rotavirusabağlı mortalitenin %80den fazlası gelişmekte olanülkelerde görülmektedir. Daha önce geçirilmiş rotavirusenfeksiyonunun sonraki atakları %77 oranında, orta- ağır şiddetteki atakları ise %87 oranında engellediğigösterilmiştir. Bu nedenle yaşamın erken dönemindekiaşılama, çocuğun ilk doğal enfeksiyonuna benzer şekil- de, şiddetli rotavirus enfeksiyon ataklarını ve buna bağlıölümleri önlemede en etkin yöntemdir. Dünya SağlıkÖrgütü monovalan veya pentavalan oral rotavirus aşı- sının ulusal bağışıklama programına alınmasını öner- mektedir. Rotavirus aşısının uygulanması sonrasındarotavirus ilişkili mortalite ve morbiditede önemli azalmagörülmüştür. Rotavirus aşı uygulaması, mortaliteninçoğunluğunun görüldüğü gelişmekte olan ülkelerdeözellikle önemlidir. (J Pediatr Inf 2015; 9: 166-74)
Anahtar Kelime: Konular:
Rotavirus Vaccines
Öz: Rotaviruses are the most common cause of severegastroenteritis in infants and children. Rotaviruses areresponsible for approximately 40% of all diarrhealhospitalizations among children under 5 years of ageworldwide. Rotavirus, which is known as democraticvirus, occurs with similar frequency in both developedand developing countries regardless of the hygieneconditions. Almost all children up to 5 years of age areinfected with rotavirus at least once. But the majorityof death cases towing to rotaviruses occur in childrenfrom resource-poor countries. Many investigatorshave reported that previous rotavirus infections pro- tect against severe disease associated with reinfec- tion. For this reason, vaccination in the early period ofinfancy is the most important method for protectionagainst severe rotavirus infections and death. WorldHealth Organization recommends rotavirus vaccina- tion. After the introduction of rotavirus vaccines, sig- nificant reduction has been seen in morbidity andmortality because of rotaviruses. Rotavirus vaccineadministration is particularly important in developingcountries where majority of death cases are observed. (J Pediatr Inf 2015; 9: 166-74)
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Liu L, Johnson HL, Cousens S, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 379: 2151-6. [CrossRef] 2. Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009; 200 Suppl 1: 9-15. [CrossRef] 3. Ceyhan M, Alhan E, Salman N, et al. Multicenter prospec- tive study on the burden of rotavirus gastroenteritis in Turkey, 2005-2006: a hospital-based study. J Infect Dis 2009; 200 Suppl 1: 234-8. [CrossRef] 4. Staat MA, McNeal MM, Bernstein DI. Rotaviruses. In Textbook of Pediatric Infectious Diseases. Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ (eds). 7th ed. Philadelphia, Saunders; 2014, pp.2176-92. 5. Glass RI, Bresee J, Jiang B, Parashar UD, Yee E, and Gentsch J. Rotavirus and rotavirus vaccines. Adv Exp Med Biol 2006; 582: 45-54. [CrossRef] 6. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD; WHO-coordinated Global Rotavirus Surveillance Network. 2008 estimate of worldwide rotavi- rus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 136-41. [CrossRef] 7. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immu- nity after neonatal rotavirus infection: a prospective longi- tudinal study in young children. N Engl J Med 1983; 309: 72-6. [CrossRef] 8. Velázquez FR, Matson DO, Calva JJ, et al. Rotavirus infec- tions in infants as protection against subsequent infecti- ons. N Engl J Med 1996; 335: 1022-8. [CrossRef] 9. Adams WR, Kraft LM. Epizootic diarrhea of infant mice: identification of the etiologic agent. Science 1963; 141: 359-60. [CrossRef] 10. Glass RI, Parashar U, Patel M, Gentsch J, Jiang B. Rotavirus vaccines: Successes and challenges. J Infect 2014; 68 Suppl 1: 9-18. [CrossRef] 11. Bishop RF, Davidson GP, Holmes IH, Ruck BJ. Virus partic- les in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet 1973; 2: 1281-3. [CrossRef] 12. Matson DO. Rotavirus vaccines for infants. http://www.upto- date.com/contents/rotavirus-vaccines-for-infants adresin- den 14/02/2015 tarihinde erişilmiştir. 13. Rotavirus. http://www.niaid.nih.gov/topics/rotavirus/Pages/ rotavirusIllustration.aspx adresinden 14/02/2015 tarihinde erişilmiştir. 14. Somer A, Törün S. Rotavirus enfeksiyonları ve rotavirus aşıları. Klinik Tıp Pediatri Dergisi 2013; 5: 11-20. 15. Dennehy PH. Rotavirus vaccines: an overview. Clin Microbiol Rev 2008; 21: 198-208. [CrossRef] 16. Santos N, Hoshino Y. Global distribution of rotavirus seroty- pes/genotypes and its implication fort the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15: 29-56. [CrossRef] 17. Durmaz R, Kalaycıoglu AT, Acar S, et al. Prevalence of rota- virus genotypes in children younger than 5 years of age before the introduction of a universal rotavirus vaccination program: report of rotavirus surveillance in Turkey. PLoS One 2014; 9: e113674. [CrossRef] 18. Dennehy PH. Rotavirus vaccines: an update. Pediatr Infect Dis J 2006; 25: 839-40. [CrossRef] 19. Ward RL, Bernstein DI. Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis 1994; 169: 900-4. [CrossRef] 20. Ward RL. Possible mechanism of protection elicited by can- didate rotavirus vaccines as determined with the adult mouse model. Viral Immunol 2003; 16: 17-24. [CrossRef] 21. Withdrawal of rotavirus vaccine recommendation http:// www.cdc.gov/mmwr/preview/mmwrhtml/mm4843a5.htm adresinden 16/02/2015 tarihinde erişilmiştir. 22. Simonsen L, Viboud C, Elixhauser A, Taylor RJ, Kapikian AZ. More on RotaShield and intussusception: the role of age at the time vaccination. J Infect Dis 2005; 192 Suppl 1: 36-43. [CrossRef] 23. Prevention of rotavirus gastroenteritis among infants and children, Recommendations of the Advisory Committee on Immunization Practices (ACIP). http://www.cdc.gov/mmwr/ preview/mmwrhtml/rr5802a1.htm adresinden 14/02/2015 tarihinde erişilmiştir. 24. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354: 23-33. [CrossRef] 25. Rotavirus vaccines. WHO position paper. http://www.who. int/wer/2013/wer8805.pdf?ua=1 adresinden 16/02/2015 tarihinde erişilmiştir. 26. 26. National and Regional Rotavirus Vaccine Introductions. http://rotacouncil.org/toolkit/national-and-regional- rotavirus-introductions/ adresinden 22/02/2015 tarihinde erişilmiştir. 27. Tate JE, Mutuc JD, Panozzo CA, et al. Sustained decline in rotavirus detections in the United States following the intro- duction of rotavirus vaccine in 2006. Pediatr Infect Dis J 2011; 30 Suppl 1: 30-4. [CrossRef] 28. Begue RE, Perrin K. Reduction in gastroenteritis with the use of pentavalent rotavirus vaccine in a primary practice. Pediatrics 2010; 126: e40-5. [CrossRef] 29. Cortese MM, Tate JE, Simonsen L, Edelman L, Parashar UD. Reduction in gastroenteritis in United States children and correlation with early rotavirus vaccine uptake from national medical claims databases. Pediatr Infect Dis J 2010; 29: 489-94. [CrossRef] 30. Curns AT, Steiner CA, Barrett M, Hunter K, Wilson E, Parashar UD. Reduction in acute gastroenteritis hospitali- zations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 2010; 201: 1617-24. [CrossRef] 31. Yen C, Tate JE, Wenk JD, Harris JM 2nd, Parashar UD. Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics 2011; 127: e9-15. [CrossRef] 32. Payne DC, Staat MA, Edwards KM, et al. Direct and indi- rect effects of rotavirus vaccination upon childhood hospi- talizations in 3 US Counties, 2006-2009. Clin Infect Dis 2011; 53: 245-53. [CrossRef] 33. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from child- hood diarrhea in Mexico. N Engl J Med 2010; 362: 299- 305. [CrossRef] 34. Yen C, Cortese MM. Rotaviruses. In: Principal and Practice of Pediatric Infectious Disease. Long SS, Pickering LK, Prober CG (eds). 4th ed. Philadelphia, Saunders; 2012, pp.1094-7. 35. Buttery JP, Danchin MH, Lee KJ, et al. Intussusception follo- wing rotavirus vaccine administration: post-marketing sur- veillance in the National Immunization Program in Australia. Vaccine 2011; 29: 3061-6. [CrossRef] 36. Patel MM, López-Collada VR, Bulhões MM, et al. Intussusception risk and health benefits of rotavirus vacci- nation in Mexico and Brazil. N Engl J Med 2011; 364: 2283- 92. [CrossRef] 37. Loughlin J, Mast TC, Doherty MC, Wang FT, Wong J, Seeger JD. Post marketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr Infect Dis J 2012;31: 292-6. [CrossRef] 38. Payne DC, Baggs J, Zerr DM, et al. Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. Clin Infect Dis 2014; 58: 173-7. [CrossRef] 39. Bresee JS, Parashar UD, Widdowson MA, Gentsch JR, Steele AD, Glass RI. Update on rotavirus vaccines. Pediatr Infect Dis J 2005; 24: 947-52. [CrossRef] 40. Bines JE, Kirkwood CD. Conquering rotavirus: from disco- very to global vaccine implementation. J Paediatr Child Health 2015; 51: 34-9. [CrossRef] 41. Rotavirus infections. In: Red Book 2012: Report of the Committee on Infectious Diseases. Pickering LK, Baker CJ, Kimberlin DW, Long SS (eds). 29th ed. Elk Grove Village IL, American Academy of Pediatrics. 2012; p. 626-9.
| APA | kocabas e, DAYAR TİMURTAŞ G (2015). Rotavirus Aşıları. , 166 - 174. |
| Chicago | kocabas emine,DAYAR TİMURTAŞ Gülperi Rotavirus Aşıları. (2015): 166 - 174. |
| MLA | kocabas emine,DAYAR TİMURTAŞ Gülperi Rotavirus Aşıları. , 2015, ss.166 - 174. |
| AMA | kocabas e,DAYAR TİMURTAŞ G Rotavirus Aşıları. . 2015; 166 - 174. |
| Vancouver | kocabas e,DAYAR TİMURTAŞ G Rotavirus Aşıları. . 2015; 166 - 174. |
| IEEE | kocabas e,DAYAR TİMURTAŞ G "Rotavirus Aşıları." , ss.166 - 174, 2015. |
| ISNAD | kocabas, emine - DAYAR TİMURTAŞ, Gülperi. "Rotavirus Aşıları". (2015), 166-174. |
| APA | kocabas e, DAYAR TİMURTAŞ G (2015). Rotavirus Aşıları. Çocuk Enfeksiyon Dergisi, 9(4), 166 - 174. |
| Chicago | kocabas emine,DAYAR TİMURTAŞ Gülperi Rotavirus Aşıları. Çocuk Enfeksiyon Dergisi 9, no.4 (2015): 166 - 174. |
| MLA | kocabas emine,DAYAR TİMURTAŞ Gülperi Rotavirus Aşıları. Çocuk Enfeksiyon Dergisi, vol.9, no.4, 2015, ss.166 - 174. |
| AMA | kocabas e,DAYAR TİMURTAŞ G Rotavirus Aşıları. Çocuk Enfeksiyon Dergisi. 2015; 9(4): 166 - 174. |
| Vancouver | kocabas e,DAYAR TİMURTAŞ G Rotavirus Aşıları. Çocuk Enfeksiyon Dergisi. 2015; 9(4): 166 - 174. |
| IEEE | kocabas e,DAYAR TİMURTAŞ G "Rotavirus Aşıları." Çocuk Enfeksiyon Dergisi, 9, ss.166 - 174, 2015. |
| ISNAD | kocabas, emine - DAYAR TİMURTAŞ, Gülperi. "Rotavirus Aşıları". Çocuk Enfeksiyon Dergisi 9/4 (2015), 166-174. |
